Zolpidem
This sedative-hypnotic medication is widely prescribed for short-term treatment of insomnia, helping people fall asleep more quickly and stay asleep longer. It works by binding to GABA receptors in the brain in a targeted way to produce sedation without the same degree of anxiety relief as benzodiazepines. Complex sleep behaviors including sleepwalking, sleep-driving, and sleep-eating have been reported, and women typically require a lower dose due to slower drug clearance.
Moleküler Ağırlık
307,3950 g/mol
LogP
2,50
TPSA
37,60 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
İlaç Sınıfları
Etki Mekanizması
Selective GABA-A receptor alpha-1 subunit agonist.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective GABA-A receptor alpha-1 subunit agonist.
2D Yapı
Cite this structure
Embed this structure
SMILES
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
InChI
InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
Molecular Formula
C19H21N3O
HBD / HBA
- / 2
Döndürülebilir Bağlar
3
Ağır Atomlar
23
Combining alprazolam with zolpidem produces additive CNS depression, profound sedation, psychomotor impairment, and respiratory depression risk.
Diazepam and zolpidem together produce compounded GABA-A-mediated CNS depression, with risk of severe sedation and respiratory compromise.
Zolpidem has been reported to modestly increase warfarin anticoagulation in isolated case reports; routine clinical concern is low.
Gabapentin adds to zolpidem's CNS depressant effects, increasing the risk of excessive sedation, falls, and next-morning psychomotor impairment.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This sedative-hypnotic medication is widely prescribed for short-term treatment of insomnia, helping people fall asleep more quickly and stay asleep longer. It works by binding to GABA receptors in the brain in a targeted way to produce sedation without the same degree of anxiety relief as benzodiazepines. Complex sleep behaviors including sleepwalking, sleep-driving, and sleep-eating have been reported, and women typically require a lower dose due to slower drug clearance.
Selective GABA-A receptor alpha-1 subunit agonist.
Key pharmacokinetic parameters for Zolpidem: Half-life: 2.5 hours.
Yes, Zolpidem is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL911. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5732. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zolpidem"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zolpidem/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zolpidem/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zolpidem/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zolpidem"></drugfyi-drug>